Eli Lilly Crushes Q2 Expectations as Weight-Loss Drug Sales Skyrocket

cnbc · 2026-08-05T10:45:42+00:00

Eli Lilly reported strong second-quarter results, beating Wall Street estimates on the back of surging demand for its Mounjaro and Zepbound treatments.